Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
Journal of Clinical Oncology · 20.06.2023 · 41 (18) · 3352-3362
DOI: 10.1200/jco.22.02394 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2023. Verfasst von Michael J Morris und 22 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. PATIENTS AND METHODS Men with untreated mCRPC were randomly assigned (1:1) to receive first-line enzalutamide with or without AAP. The primary end point was OS. Toxicity, prostate-specific antigen declines, pharmacokinetics, and radiographic progression-free survival (rPFS) were also examined. Data were analyzed using an intent-to-treat approach. The Kaplan-Meier estimate and the stratified log-rank statistic were used to compare OS between treatments. RESULTS In total, 1,311 patients were randomly assigned: 657 to enzalutamide and 654 to enzalutamide plus AAP. OS was not statistically different between the two arms (median, 32.7 [95% CI, 30.5 to 35.4] months for enzalutamide v 34.2 [95% CI, 31.4 to 37.3] months for enzalutamide and AAP; hazard ratio [HR], 0.89; one-sided P = .03; boundary nominal significance level = .02). rPFS was longer in the combination arm (median rPFS, 21.3 [95% CI, 19.4 to 22.9] months for enzalutamide v 24.3 [95% CI, 22.3 to 26.7] months for enzalutamide and AAP; HR, 0.86; two-sided P = .02). However, pharmacokinetic clearance of abiraterone was 2.2- to 2.9-fold higher when administered with enzalutamide, compared with clearance values for abiraterone alone. CONCLUSION The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Alliance Statistics and Data Management Center, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
- Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
- Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
- University of Chicago Medical Center, Chicago, IL.
ORCID-Profile: Michael J Morris, David W Hillman, Olivia Bobek, Emmanuel S Antonarakis, Alan H Bryce, Himisha Beltran, Andrew J Armstrong, Jan H Beumer, Amir Goldkorn, Bruce J Roth, Han Xiao, Susan Halabi, Eric J Small
Förderung
- NCI NIH HHS
Zitieren
APA
Morris, M. J., Heller, G., Hillman, D. W., Bobek, O., Ryan, C., Antonarakis, E. S., Bryce, A. H., Hahn, O., Beltran, H., Armstrong, A. J., Schwartz, L., Lewis, L. D., Beumer, J. H., Langevin, B., McGary, E. C., Mehan, P. T., Goldkorn, A., Roth, B. J., Xiao, H., …, & Small, E. J. (2023). Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology, 41(18), 3352-3362. https://doi.org/10.1200/jco.22.02394
Vancouver
Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, et al. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology. 2023;41(18):3352-3362. doi:10.1200/jco.22.02394
BibTeX
@article{Morris2023,
author = {Morris, Michael J and Heller, Glenn and Hillman, David W and Bobek, Olivia and Ryan, Charles and Antonarakis, Emmanuel S and Bryce, Alan H and Hahn, Olwen and Beltran, Himisha and Armstrong, Andrew J and Schwartz, Lawrence and Lewis, Lionel D and Beumer, Jan H and Langevin, Brooke and McGary, Eric C and Mehan, Paul T and Goldkorn, Amir and Roth, Bruce J and Xiao, Han and Watt, Colleen and Taplin, Mary-Ellen and Halabi, Susan and Small, Eric J},
title = {Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {18},
pages = {3352--3362},
doi = {10.1200/jco.22.02394}
}
EUVIMED